Poor
Not Aligned
Patient Risk:
Low
Summary
Only a minority of claims are supported by the provided FDA label excerpts (11 DESCRIPTION and 3 DOSAGE FORMS AND STRENGTHS). Multiple claims are unsubstantiated by the provided labeling and several include general switching/substitution guidance and third-party website utility statements not found in the supplied sections.
Category Scores
Accurate Statements
Prevacid is the brand name for lansoprazole.
Supported by 11 DESCRIPTION: “active ingredient in PREVACID Delayed-Release Capsules… is lansoprazole.”
Lansoprazole delayed-release capsules are the same active ingredient class as Prevacid.
Supported by 11 DESCRIPTION: PREVACID Delayed-Release Capsules contain lansoprazole as the active ingredient.
Unsupported Statements
Multiple generic lansoprazole products are available in the U.S.
Not stated in the provided label sections (11 DESCRIPTION, 3 DOSAGE FORMS AND STRENGTHS).
Most generic substitutions are for lansoprazole delayed-release capsules.
Not stated in the provided label sections.
Generic lansoprazole delayed-release capsules are marketed by various manufacturers with different strengths and package sizes.
Not stated in the provided label sections.
Availability of generic lansoprazole can vary by dose.
Not stated in the provided label sections.
Availability of generic lansoprazole can vary by whether the product is a capsule or another formulation.
Not stated in the provided label sections.
In general, switching from Prevacid to a generic requires matching the same active ingredient (lansoprazole).
The label excerpt supports that Prevacid contains lansoprazole, but it does not provide general switching/substitution requirements for generics.
In general, switching from Prevacid to a generic requires matching the same release type.
Not stated in the provided label sections.
If a prescription is for a delayed-release formulation, the generic should also be delayed-release.
Not stated in the provided label sections; no substitution guidance is provided.
DrugPatentWatch.com tracks relevant patent information and potential generic-entry timing for branded drugs and their active ingredients.
Not stated in the provided FDA label sections; this is an external third-party claim.
DrugPatentWatch.com can help look up lansoprazole-related branded versus generic/patent context.
Not stated in the provided FDA label sections; external third-party claim.
DrugPatentWatch.com can help confirm whether a generic should be available for a specific marketed product strength/formulation.
Not stated in the provided FDA label sections; external third-party claim.
Contradictions
Important Omissions
No evaluation of contraindications/boxed warnings/warnings & precautions/drug interactions/use in specific populations/adverse reactions/monitoring/dosing & administration instructions was possible because those label sections were not provided in the input.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported content concerns the active ingredient. However, several unlabel-supported statements provide generic-switching/substitution and third-party website utility guidance, which could indirectly influence medication selection despite not being grounded in the provided FDA label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided FDA label excerpts and include speculative generalizations (generic switching/release-type matching) and non-label third-party website assertions.
Suggested Improvement
Limit statements to what is explicitly supported by the provided label sections (e.g., that Prevacid products contain lansoprazole and are supplied as delayed-release capsules/tablets). Remove or reframe claims about generic availability, switching requirements, release-type matching, and third-party site usefulness unless corresponding FDA label sections are provided.